HARROW, INC.
HROW · XNASCIK 1360214fmd_0CWHBD57ZZY22ZEJAVZYX1D4RHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 1998 to Sep 30, 2026, 78 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 20 | 27 | 41 | 51 | 49 | 72 | 89 | 130 | 200 | 272 |
| Net interest income | (3) | (3) | (3) | (3) | (2) | (5) | – | – | – | – |
| Cost of revenue | – | 14 | 17 | 17 | 14 | 18 | 25 | 40 | 49 | 68 |
| Gross profit | 10 | 13 | 25 | 34 | 34 | 54 | 63 | 91 | 150 | 204 |
| Realized investment gains (losses) | – | – | – | – | – | (10) | (3) | 3 | (3) | – |
| Research and development | 1 | 0 | 1 | 2 | 2 | 11 | 3 | 7 | 12 | 21 |
| Selling, general and administrative | 25 | 25 | 29 | 33 | 31 | 41 | 58 | 83 | 129 | 153 |
| Total operating expenses | – | 25 | 30 | 39 | 34 | 53 | 61 | 90 | 142 | 174 |
| Operating income | (16) | (12) | (5) | (5) | 0 | 2 | 2 | 0 | 9 | 31 |
| Interest expense | – | – | – | – | – | 5 | 7 | 21 | 23 | 24 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (3) | (1) | 20 | 5 | (4) | (19) | (16) | (24) | (26) | (32) |
| Income before taxes | (19) | (13) | 15 | (0) | (3) | (18) | (14) | (24) | (17) | (1) |
| Income tax expense | (0) | (1) | – | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
| Net income from continuing operations | (19) | (12) | – | (0) | (3) | (18) | (14) | (24) | (17) | (5) |
| Net income | (19) | (12) | 15 | 0 | (3) | (18) | (14) | (24) | (17) | (5) |
| Net income to common shareholders | – | – | – | – | (3) | (18) | (14) | (24) | (17) | – |